奥昔嘌醇

奥昔嘌醇
	IUPAC名; 1H-pyrazolo[3,4-d]pyrimidine-4,6(2H,5H)-dione
别名	2,5-二氢-1H-吡唑并[3,4-d]嘧啶-4,6-二酮
识别
CAS号	2465-59-0
PubChem	4644
ChemSpider	4483
SMILES	O=C1NC(=O)C2=CNNC2=N1;
InChI	1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11);
InChIKey	HXNFUBHNUDHIGC-UHFFFAOYSA-N
Beilstein	139956
EINECS	219-570-9
ChEBI	28315
KEGG	C07599
MeSH	Oxypurinol
性质
化学式	C5H4N4O2
摩尔质量	152.11086 g·mol⁻¹
外观	白色晶体
	若非注明，所有数据均出自标准状态（25 ℃，100 kPa）下。

奥昔嘌醇（INN：oxipurinol；USAN：oxypurinol）是黄嘌呤氧化酶的抑制剂。^[1]它是别嘌醇的活性代谢物，通过肾脏清除。^[2]在患有肾脏疾病的情况下，这种代谢物会积累到有毒水平。它通过抑制黄嘌呤氧化酶，从而减少尿酸的产生。高血清尿酸水平可能会导致痛风、肾结石和其他疾病。

参考资料[编辑]

^ Stocker, Sophie L; McLachlan, Andrew J; Savic, Radojka M; Kirkpatrick, Carl M; Graham, Garry G; Williams, Kenneth M; Day, Richard O. The pharmacokinetics of oxypurinol in people with gout. British Journal of Clinical Pharmacology. 2012, 74 (3): 477–489. PMC 3477349 . PMID 22300439. doi:10.1111/j.1365-2125.2012.04207.x.
^ Elion, Gertrude B; Yü, Ts'ai-Fan; Gutman, Alexander B; Hitchings, George H. Renal clearance of oxipurinol, the chief metabolite of allopurinol. The American Journal of Medicine. 1968, 45 (1): 69–77. PMID 5658870. doi:10.1016/0002-9343(68)90008-9.

[1] Stocker, Sophie L; McLachlan, Andrew J; Savic, Radojka M; Kirkpatrick, Carl M; Graham, Garry G; Williams, Kenneth M; Day, Richard O. The pharmacokinetics of oxypurinol in people with gout. British Journal of Clinical Pharmacology. 2012, 74 (3): 477–489. PMC 3477349 . PMID 22300439. doi:10.1111/j.1365-2125.2012.04207.x.

[2] Elion, Gertrude B; Yü, Ts'ai-Fan; Gutman, Alexander B; Hitchings, George H. Renal clearance of oxipurinol, the chief metabolite of allopurinol. The American Journal of Medicine. 1968, 45 (1): 69–77. PMID 5658870. doi:10.1016/0002-9343(68)90008-9.

[1]

[2]